It's finally here...



The more pleasant way to screen for colon cancer.

Answer three quick questions to see if you're eligible for colon cancer screening and if Shield, a blood-based screening test, may be right for you:

		Yes	No
1	Are you 45–85 years old?*		
2	 Are you at average risk for colon cancer? Answer "Yes" if you have: No prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease. No personal diagnosis or family history of colorectal cancer or known genetic disorders such as Lynch syndrome or familial adenomatous polyposis. 		
3	Are you due for colon cancer screening?		



Colonoscopy within the last 10 years



Either of the following stool tests:

- FIT/FOBT in the last year
- FIT-DNA in the last 1-3 years

If all three answers are "Yes," you may be eligible for colon cancer screening.

Answer "No" if you have completed any of the following screening tests:

Shield is Medicare covered. Patients with Medicare Part-B will have \$0 out-of-pocket costs for Shield*.

Kindly return this form to your healthcare provider.

- Discuss the benefits and risks of screening with Shield as part of a shared decision made with your healthcare provider.
- Share your medical history with your healthcare provider to assess your eligibility.
- Shield is not a replacement for a follow-up diagnostic colonoscopy or for surveillance colonoscopy in high risk individuals. Shield has limited ability to prevent the development of colorectal cancer from advanced precancerous lesions



*Eligible Medicare Fee for Service (FFS) patients will have \$0 out-of-pocket cost for Shield. Patients with Medicare Advantage may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan. Patients not covered by Medicare may have an out-of-pocket cost.

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.

Shield is indicated for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stage II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not indicated for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn's disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please visit ShieldCancerScreen.com for complete product information about the Shield test including full safety information.